

An ISIRV-WHO Virtual Conference  
**COVID-19, INFLUENZA AND RSV:  
 SURVEILLANCE-INFORMED  
 PREVENTION AND TREATMENT**

**DATES** 19–21 OCTOBER 2021

**TIMES**  
 7.00am-11.30am EDT  
 12.00pm-4.30pm UK  
 1.00pm-5.30pm CEST  
 7.00pm-11.30pm CST  
 AND AVAILABLE ON DEMAND

<b>Tuesday 19 October (times in CEST)</b>	
<b>13:00-13:10</b>	<b>Welcome</b> WHO Director-General Tedros Adhanom Ghebreyesus, WHO, Geneva, Switzerland, Maria Zambon (Chair of ISIRV), PHE, London, UK & Frederick Hayden, University of Virginia, Charlottesville, VA, USA
<b>13:10-15:55</b>	<b>Session 1: Pandemic Response and Surveillance</b> Co-Chairs: Rick Bright, The Rockefeller Foundation, Washington, D.C., USA & John McCauley, The Francis Crick Institute, London, UK
<b>13:10-13:50</b>	<b>Keynote Talk</b> COVID-19 Pandemic: Response and Preparing for the Future <i>Mike Ryan, WHO, Geneva, Switzerland</i>
<b>13:50-14:15</b>	How do Respiratory Viruses Cause Diseases? <i>Yoshi Kawaoka, University of Wisconsin-Madison, WI, USA and University of Tokyo, Japan</i>
<b>14:15-14:40</b>	Leveraging GISRS in a Pandemic Response <i>Wenqing Zhang, WHO, Geneva, Switzerland</i>
<b>14:40-15:05</b>	SARS-CoV-2 Evolution: Implications for Vaccine Strain Selection <i>Kanta Subbarao, WHO CC for Reference and Research on Influenza, Melbourne, Australia</i>
<b>15:05-15:30</b>	Monitoring Influenza Antiviral Resistance: What Lessons are There for SARS-CoV-2 <i>Larisa Gubareva, CDC, Atlanta, GA, USA</i>
<b>15:30-15:55</b>	Animal Reservoirs and Future Risks <i>Ron Fouchier, Erasmus MC, Rotterdam, The Netherlands</i>
<b>15:55-16:05</b>	<b>Comfort Break</b>

An ISIRV-WHO Virtual Conference  
**COVID-19, INFLUENZA AND RSV:  
 SURVEILLANCE-INFORMED  
 PREVENTION AND TREATMENT**

**DATES** 19–21 OCTOBER 2021

**TIMES**  
 7.00am-11.30am EDT  
 12.00pm-4.30pm UK  
 1.00pm-5.30pm CEST  
 7.00pm-11.30pm CST  
 AND AVAILABLE ON DEMAND

16:05-17:35	<p><b>Session 2 (Oral Abstract Session 1)</b>  <b>Co-Chairs: Jake Dunning, University of Oxford, Oxford, UK &amp; Barbara Rath, Vienna Vaccine Safety Initiative, Berlin, Germany and Université de Bourgogne Franche-Comté, France</b></p>
16:05-16:20	<p>Global Conformational Shift in the Respiratory Syncytial Virus Fusion Glycoprotein by a Single Amino Acid Switch Causes Neutralizing Antibody Evasion  <i>David Marchant, University of Alberta, Edmonton, Alberta, Canada</i></p>
16:20-16:35	<p>SARS-CoV-2 Incidence, Transmission and Reinfection in a Rural and an Urban Setting: Results of the PHIRST-C Cohort Study, South Africa, 2020-2021  <i>Cheryl Cohen, National Institute for Communicable Diseases, Johannesburg, South Africa</i></p>
16:35-16:50	<p>Characterising Within-Hospital SARS-CoV-2 Transmission Events: a Retrospective Analysis Integrating Epidemiological and Viral Genomic Data From a UK Tertiary Care Setting Across Two Pandemic Waves  <i>Benjamin Lindsey, University of Sheffield, Sheffield, UK</i></p>
16:50-17:05	<p>Use of Epidemiological and Whole Genome Sequence Data to Assess Clinical Impact of Specific SARS-CoV-2 Mutations  <i>Kirstin Leslie, Public Health Scotland, Glasgow, UK</i></p>
17:05-17:20	<p>SARS-CoV-2 Variants of Concern Have Acquired Mutations Associated With an Increased Spike Cleavage  <i>Alba Escalera, Icahn School of Medicine at Mount Sinai, New York, NY, USA</i></p>
17:20-17:35	<p>Co-Infection of Chickens With H9N2 and H7N9 Avian Influenza Viruses Leads to Emergence of Reassortant H9N9 Virus With Increased Fitness for Poultry and a Zoonotic Potential  <i>Sushant Bhat, The Pirbright Institute, Woking, Surrey, UK</i></p>
17:35	Close of Day 1 and Poster Viewing

An ISIRV-WHO Virtual Conference  
**COVID-19, INFLUENZA AND RSV:  
 SURVEILLANCE-INFORMED  
 PREVENTION AND TREATMENT**

**DATES** 19–21 OCTOBER 2021

**TIMES**  
 7.00am-11.30am EDT  
 12.00pm-4.30pm UK  
 1.00pm-5.30pm CEST  
 7.00pm-11.30pm CST  
 AND AVAILABLE ON DEMAND

<p><b>Wednesday 20 October</b>  <b>(times in CEST)</b></p>	
<p><b>13:00-15:50</b></p> <p><b>13:05-13:45</b></p> <p><b>13:45-14:10</b></p> <p><b>14:10-14:35</b></p> <p><b>14:35-15:00</b></p> <p><b>15:00-15:25</b></p> <p><b>15:25-15:50</b></p>	<p><b>Session 3: Treatment</b>  <i>Co-Chairs: Frederick Hayden, University of Virginia, Charlottesville, VA, USA &amp; Bin Cao, China-Japan Friendship Hospital, Beijing, China</i></p> <p><b>Keynote Talk</b>      Severe COVID-19, Influenza, and RSV Pathogenesis: Similarities and Differences  <i>Peter Openshaw, Imperial College, London, UK</i></p> <p>Lessons Learned from Coronavirus Animal Models  <i>Timothy Sheahan, UNC, Chapel Hill, NC, USA</i></p> <p>Current Status of Antiviral Therapy for COVID-19 and Influenza: WHO Perspectives  <i>Janet Diaz, WHO, Geneva, Switzerland</i></p> <p>Immune Modulation and Biomarkers in COVID-19  <i>John Beigel, NIH, Rockville, MD, USA</i></p> <p>SARS-CoV-2 Variants: Implications for Monoclonals  <i>Tyler Starr, Fred Hutchinson Cancer Research Center, Seattle, WA, USA</i></p> <p>Long COVID: Interventions to Reduce Risk or Treat  <i>Charlotte Summers, University of Cambridge/Addenbrooke's Hospital, Cambridge, UK</i></p>
<p><b>15:50-16:00</b></p>	<p><b>Comfort Break</b></p>

An ISIRV-WHO Virtual Conference  
**COVID-19, INFLUENZA AND RSV:  
 SURVEILLANCE-INFORMED  
 PREVENTION AND TREATMENT**

**DATES** 19–21 OCTOBER 2021

**TIMES**  
 7.00am-11.30am EDT  
 12.00pm-4.30pm UK  
 1.00pm-5.30pm CEST  
 7.00pm-11.30pm CST  
 AND AVAILABLE ON DEMAND

16:00-17:30	<p><b>Session 4: (Oral Abstract Session 2)</b>  <b>Co-Chairs: Jenny McKimm-Breschkin, University of Melbourne, Melbourne, Australia &amp; Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France</b></p>
16:00-16:15	<p>Pre-Clinical Data of Ensovibep, a Multi-Specific DARPIn Therapeutic With High Potency Against All Frequent SARS-CoV-2 Variants  <i>Francesca Malvezzi, Molecular Partners AG, Schlieren, Switzerland</i></p>
16:15-16:30	<p>Antiviral and Anti-inflammatory Activity of Verdinexor  <i>Yosef Landesman, Karyopharm Therapeutics, Newton, MA, USA</i></p>
16:30-16:45	<p>S-217622, A Novel SARS-CoV-2 3C-Like Protease Inhibitor Clinical Candidate As a Potential Oral Therapeutic Agent for COVID-19  <i>Yuki Tachibana, Shionogi &amp; Co., Ltd., Osaka, Japan</i></p>
16:45-17:00	<p>Lack of Antiviral Activity of Probenecid in Vero E6 Cells and Syrian Golden Hamsters: a Need for Better Understanding of Inter-Lab Differences in Preclinical Assays.  <i>Helen Box, University of Liverpool, Liverpool, UK</i></p>
17:00-17:15	<p>Interim Results from a Phase 2 Randomized, Placebo-Controlled Study Evaluating AT-527 in High-Risk Hospitalized Patients With Moderate COVID-19  <i>Daniel Kuritzkes, Brigham and Women's Hospital, Boston, MA, USA</i></p>
17:15-17:30	<p>The Casirivimab and Imdevimab Combination Therapy Improves How Outpatients With COVID-19 Feel and Function  <i>Diana Rofail, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA</i></p>
17:30	<p>Close of Day 2 and Poster Viewing</p>

An ISIRV-WHO Virtual Conference  
**COVID-19, INFLUENZA AND RSV:  
 SURVEILLANCE-INFORMED  
 PREVENTION AND TREATMENT**

**DATES** 19–21 OCTOBER 2021

**TIMES**  
 7.00am-11.30am EDT  
 12.00pm-4.30pm UK  
 1.00pm-5.30pm CEST  
 7.00pm-11.30pm CST  
 AND AVAILABLE ON DEMAND

<b>Thursday 21 October</b> <b>(times in CEST)</b>	
<b>11:00-12:15</b>	<p><b>WHO Special Session: Influenza Surveillance, Preparedness and Response in Conflict Affected Settings</b></p> <p>Moderator: <i>Wasiq Khan, WHO Regional Office for the Eastern Mediterranean (WHO/EMRO)</i></p> <p>Opening remarks: <i>Abdinasir Abubakar, WHO Regional Office for the Eastern Mediterranean (EMRO)</i></p> <ul style="list-style-type: none"> <li>➤ Country experience and perspective: Influenza Programme Afghanistan - <i>Hafizullah Safi</i></li> <li>➤ Country experience and perspective: Influenza Programme Syria- <i>Rasmieh Allahham</i></li> <li>➤ Preventing pandemics in world’s most vulnerable settings: WHO EMRO and Duke University – <i>Gavin Yamey</i></li> <li>➤ Zoonotic influenza surveillance and preparedness in Eastern Mediterranean Region: WHO EMRO and Human Link – <i>Ghazi Kayali</i></li> <li>➤ Concluding remarks: <i>Wenqing Zhang, Global Influenza Programme WHO</i></li> </ul>
<b>13:00-15:00</b>  <b>13:05-13:45</b>  <b>13:45-14:10</b>  <b>14:10-14:35</b>  <b>14:35-15:00</b>	<p><b>Session 5: Prevention and Response</b>  <i>Co-Chairs: Ann Moen, US CDC, Atlanta, GA, USA &amp; Michael Ison, Northwestern University, Chicago, IL, USA</i></p> <p><b>Keynote Talk</b>      Novel Vaccines for COVID-19, Influenza, and RSV  <i>Barney Graham, NIH, Rockville, MD, USA</i></p> <p>Non-Pharmaceutical Interventions to Prevent RVIs  <i>Ben Cowling, University of Hong Kong, Hong Kong SAR, China</i></p> <p>Preventing RVIs in Pregnant Women and Infants  <i>Marta Nunes, Wits Vaccines &amp; Infectious Diseases Analytics (VIDA) Research Unit, Johannesburg, South Africa</i></p> <p>Outbreak Risk Communication: Role of the Media  <i>Glen Nowak, University of Georgia, Athens, GA, USA</i></p>

An ISIRV-WHO Virtual Conference  
**COVID-19, INFLUENZA AND RSV:  
 SURVEILLANCE-INFORMED  
 PREVENTION AND TREATMENT**

**DATES** 19–21 OCTOBER 2021

**TIMES**  
 7.00am-11.30am EDT  
 12.00pm-4.30pm UK  
 1.00pm-5.30pm CEST  
 7.00pm-11.30pm CST  
 AND AVAILABLE ON DEMAND

15:00-15:10	<b>Comfort Break</b>
15:10-16:40	<b>Session 6: (Oral Abstract Session 3)</b> <b>Co-Chairs: Rebecca Cox, University of Bergen, Norway &amp; Michael Osterholm, University of Minnesota, Minneapolis, MN, USA</b>
15:10-15:25	<p>Global Study of Adults Hospitalized with Influenza, Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV): Risk Factors, Clinical Characteristics and Outcomes  <i>Ann Falsey, University of Rochester School of Medicine, Rochester, NY, USA</i></p>
15:25-15:40	<p>Impact of the COVID-19 Nonpharmaceutical Interventions on Influenza and Other Respiratory Viral Infections in New Zealand  <i>Sue Huang, WHO National Influenza Centre, Wellington, New Zealand</i></p>
15:40-15:55	<p>An mRNA Influenza T-Cell Vaccine Boosts Existing Cellular Responses and Enhances Protection Against Severe Pneumonia Induced by H7N9 Challenge in Ferrets  <i>Jorgen de Jonge, National Institute of Public Health and the Environment (RIVM), Bilthoven, Utrecht, The Netherlands</i></p>
15:55-16:10	<p>Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine for the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease by Age Subgroups in Adults Aged 65 Years or Older in a Randomized, Placebo-controlled, Phase 2b Study  <i>Christy Comeaux, Janssen Vaccines &amp; Prevention BV, Leiden, The Netherlands</i></p>
16:10-16:25	<p>Association Between Influenza Vaccination and COVID-19, Hospitalization, and Mortality  <i>Seyed M Hosseini-Moghaddam, University of Toronto, Toronto, ON, Canada</i></p>
16:25-16:40	<p>Immunological Imprinting of the Antibody Response in COVID-19 Patients  <i>Teresa A. Aydillo Gomez, Icahn School of Medicine at Mount Sinai, New York, NY, USA</i></p>

An ISIRV-WHO Virtual Conference

**COVID-19, INFLUENZA AND RSV:  
SURVEILLANCE-INFORMED  
PREVENTION AND TREATMENT**

**DATES** 19–21 OCTOBER 2021

**TIMES**

7.00am-11.30am EDT  
12.00pm-4.30pm UK  
1.00pm-5.30pm CEST  
7.00pm-11.30pm CST

AND AVAILABLE ON DEMAND




<p><b>16:40-17:20</b></p>	<p><b>Session 7: Panel Discussion</b></p> <p><b>Preparing for the Next Event: Surveillance, Clinical Research, and Prevention Strategies</b></p> <p>Chair: <a href="#">Michael Jacobs</a></p> <p>Discussants: <a href="#">Ben Cowling</a>, <a href="#">Peter Horby</a>, <a href="#">Ann Moen</a>, <a href="#">Vasee Moorthy</a>, <a href="#">Samba Sow</a> &amp; <a href="#">Maria Zambon</a></p>
<p><b>17:20-17:30</b></p>	<p>Close of Conference</p>